Allos Looks To ENRICH Trial To Secure Excelar Approval
FDA’s Oncologic Drugs Advisory Committee says product requires confirmatory data for approval in brain metastases related to breast cancer. Open-label study began in February.
FDA’s Oncologic Drugs Advisory Committee says product requires confirmatory data for approval in brain metastases related to breast cancer. Open-label study began in February.